Sensus Healthcare
Sensus Healthcare
SRTS
NASDAQ
6.52
USD
-9.57%
About
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision.
SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Its SRT-100+ offer remote diagnostics solutions, including operation tracking..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 215.1K |
| Three Month Average Volume | 4.4M |
| High Low | |
| Fifty-Two Week High | 7.18 USD |
| Fifty-Two Week Low | 1.79 USD |
| Fifty-Two Week High Date | 20 Aug 2024 |
| Fifty-Two Week Low Date | 10 Nov 2023 |
| Price and Volume | |
| Current Price | 6.52 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 2.69% |
| Thirteen Week Relative Price Change | 12.40% |
| Twenty-Six Week Relative Price Change | 43.58% |
| Fifty-Two Week Relative Price Change | 67.31% |
| Year-to-Date Relative Price Change | 133.30% |
| Price Change | |
| One Day Price Change | 0.93% |
| Thirteen Week Price Change | 20.30% |
| Twenty-Six Week Price Change | 57.87% |
| Five Day Price Change | -0.91% |
| Fifty-Two Week Price Change | 109.65% |
| Year-to-Date Price Change | 176.27% |
| Month-to-Date Price Change | 2.35% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.98287 USD |
| Book Value Per Share (Most Recent Quarter) | 3.22667 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.98287 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.22667 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 0.53793 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.50036 USD |
| Revenue Per Share (Trailing Twelve Months) | 2.2304 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 0.02982 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 0.40716 USD |
| Normalized (Last Fiscal Year) | 0.0279 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 0.02983 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.40802 USD |
| Including Extraordinary Items (Last Fiscal Year) | 0.02982 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 0.40716 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.41369 USD |
| Cash Per Share (Most Recent Quarter) | 1.15719 USD |
| Cash Flow Per Share (Last Fiscal Year) | 0.04672 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 0.42103 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.0671 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -6 |
| Cash Flow Revenue (Trailing Twelve Months) | -3 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 26.18% |
| Pretax Margin (Last Fiscal Year) | 2.67% |
| Pretax Margin (5 Year) | 18.24% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 57.61% |
| Gross Margin (Trailing Twelve Months) | 60.23% |
| Gross Margin (5 Year) | 62.85% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1.57% |
| Operating Margin (Trailing Twelve Months) | 23.51% |
| Operating Margin (5 Year) | 7.31% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 1.99% |
| Net Profit Margin (Trailing Twelve Months) | 18.27% |
| Net Profit Margin (5 Year) | 15.29% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 12.68% |
| Tangible Book Value (5 Year) | 13.42% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 104.09% |
| Revenue Growth (3 Year) | -1.58% |
| Revenue Change (Trailing Twelve Months) | 21.00% |
| Revenue Per Share Growth | -4.33% |
| Revenue Growth (5 Year) | 36.59% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -23.16% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 522.11% |
| EPS Change (Trailing Twelve Months) | 186.47% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -18,972,000 |
| Net Debt (Last Fiscal Year) | -23,148,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 4 |
| Price to Sales (Trailing Twelve Months) | 3 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 16 |
| PE Normalized (Last Fiscal Year) | 234 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 13 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 81 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 5 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 16 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 8 |
| Quick Ratio (Most Recent Quarter) | 8 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 158 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 13 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 12 |
| Current Ratio (Most Recent Quarter) | 12 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -2,374,000 |
| Free Cash Flow (Trailing Twelve Months) | -1,094,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 0.88% |
| Return on Assets (Trailing Twelve Months) | 12.06% |
| Return on Assets (5 Year) | 10.29% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 1.00% |
| Return on Equity (Trailing Twelve Months) | 13.44% |
| Return on Equity (5 Year) | 12.60% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 0.98% |
| Return on Investment (Trailing Twelve Months) | 13.25% |
| Return on Investment (5 Year) | 12.14% |